Evaluation of 309 molecules as inducers of CYP3A4, CYP2B6, CYP1A2, OATP1B1, OCT1, MDR1, MRP2, MRP3 and BCRP in cryopreserved human hepatocytes in sandwich culture

被引:32
|
作者
Badolo, Lassina [1 ,2 ]
Jensen, Bente [1 ,2 ]
Sall, Carolina [1 ,2 ]
Norinder, Ulf [1 ,2 ]
Kallunki, Pekka [3 ]
Montanari, Dino [1 ,2 ]
机构
[1] H Lundbeck & Co AS, Discovery Chem, Copenhagen, Denmark
[2] H Lundbeck & Co AS, DMPK, Copenhagen, Denmark
[3] H Lundbeck & Co AS, Dept Neurodegenerat, Copenhagen, Denmark
关键词
Cytochrome P450; cryopreserved human hepatocytes; drug-drug interactions; hepatic transporters; induction; sandwich culture; DRUG-DRUG INTERACTIONS; CYTOCHROME-P450; ENZYMES; RAT HEPATOCYTES; INDUCTION; EXPRESSION; XENOBIOTICS; METABOLISM; RECEPTORS; TIME; TRANSPORTERS;
D O I
10.3109/00498254.2014.955831
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Regulation of hepatic metabolism or transport may lead to increase in drug clearance and compromise efficacy or safety. In this study, cryopreserved human hepatocytes were used to assess the effect of 309 compounds on the activity and mRNA expression (using qPCR techniques) of CYP1A2, CYP2B6 and CYP3A4, as well as mRNA expression of six hepatic transport proteins: OATP1B1 (SCLO1B1), OCT1 (SLC22A1), MDR1 (ABCB1), MRP2 (ABCC2), MRP3 (ABCC3) and BCRP (ABCG2). The results showed that 6% of compounds induced CYP1A2 activity (1.5-fold increase); 30% induced CYP2B6 while 23% induced CYP3A4. qPCR data identified 16, 33 or 32% inducers of CYP1A2, CYP2B6 or CYP3A4, respectively. MRP2 was induced by 27 compounds followed by MDR1 (16) > BCRP (9) > OCT1 (8) > OATP1B1 (5) > MRP3 (2). CYP3A4 appeared to be down-regulated (>= 2-fold decrease in mRNA expression) by 53 compounds, 10 for CYP2B6, 6 for OCT1, 4 for BCRP, 2 for CYP1A2 and OATP1B1 and 1 for MDR1 and MRP2. Structure-activity relationship analysis showed that CYP2B6 and CYP3A4 inducers are bulky lipophilic molecules with a higher number of heavy atoms and a lower number of hydrogen bond donors. Finally, a strategy for testing CYP inducers in drug discovery is proposed.
引用
收藏
页码:177 / 187
页数:11
相关论文
共 50 条
  • [21] Downregulation of CYP1A2, CYP2B6, and CYP3A4 in Human Hepatocytes by Prolyl Hydroxylase Domain 2 Inhibitors via Hypoxia-Inducible Factor-α Stabilization
    Takano, Hiroki
    Yamaguchi, Jun-ichi
    Kato, Sota
    Hamada, Makoto
    Tada, Mika
    Endo, Hiromi
    DRUG METABOLISM AND DISPOSITION, 2021, 49 (01) : 20 - 30
  • [22] Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2
    Rhodes, Susan P.
    Otten, Jennifer N.
    Hingorani, Gary P.
    Hartley, Dylan P.
    Franklin, Ronald B.
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2011, 63 (03) : 223 - 226
  • [23] The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine
    Eiermann, B
    Engel, G
    Johansson, I
    Zanger, UM
    Bertilsson, L
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (05) : 439 - 446
  • [24] Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects
    Ulvestad, M.
    Skottheim, I. B.
    Jakobsen, G. S.
    Bremer, S.
    Molden, E.
    Asberg, A.
    Hjelmesaeth, J.
    Andersson, T. B.
    Sandbu, R.
    Christensen, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (03) : 275 - 282
  • [25] Evaluating the Dynamics of Cyp3all, MRP2 and MDR1 Modulation by IL-22
    Delanne-Cumenal, Ameline
    Flannigan, Kyle L.
    Hirota, Simon A.
    PHYSIOLOGY, 2024, 39
  • [26] Genetic variation in the 3′-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: potential effects on regulation by microRNA and pharmacogenomics relevance
    Swart, Marelize
    Dandara, Collet
    FRONTIERS IN GENETICS, 2014, 5
  • [27] DECREASED EXPRESSION OF CYP1A2, CYP2E1, AND CYP3A4; AND DRUG TRANSPORTERS NTCP, OCT1, AND OATP-C CORRELATES WITH THE PROGRESSION OF LIVER FIBROSIS IN CHRONIC HEPATITIS C PATIENTS
    Nakai, Kenya
    Tanaka, Hiromasa
    Hanada, Kazuhiko
    Ogata, Hiroyasu
    Suzuki, Fumitaka
    Kumada, Hiromitsu
    Miyajima, Atsuko
    Ishida, Seiichi
    Sunouchi, Momoko
    Ozawa, Shogo
    Ohno, Yasuo
    DRUG METABOLISM REVIEWS, 2007, 39 : 141 - 142
  • [28] CHARACTERIZATION OF THE TRANSCELLULAR TRANSPORT PROPERTIES OF OATP1B3 SUBSTRATES IN NEW VERSIONS OF DOUBLE TRANSFECTED MDCK II CELLS, OATP1B3/MDR1, OATP1B3/MRP2 AND OATP1B3/BCRP
    Saito, Asami
    Ishiguro, Naoki
    Maeda, Kazuya
    Kishimoto, Wataru
    Ebner, Thomas
    Roth, Willy
    Igarashi, Takashi
    Sugiyama, Yuichi
    DRUG METABOLISM REVIEWS, 2007, 39 : 168 - 169
  • [29] Influence of genetic polymorphisms of uptake (OATP1B1) and efflux (BCRP/MRP2) transporters on the pharmacokinetics of rosuvastatin
    Tian, Lei
    Jiang, Juanjuan
    Liu, Hong
    Han, Lulu
    Huang, Yiling
    Li, Yishi
    CARDIOLOGY, 2013, 126 : 44 - 45
  • [30] Anti-CD28 Monoclonal Antibody-Stimulated Cytokines Released from Blood Suppress CYP1A2, CYP2B6, and CYP3A4 in Human Hepatocytes In Vitro
    Czerwinski, Maciej
    Kazmi, Faraz
    Parkinson, Andrew
    Buckley, David B.
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (01) : 42 - 52